|
|
|
State of the art Non-Sterile facility situated in the Arabian Gulf with regulatory approvals from Australia, UK, Germany, Oman, GCC and soon USA
Products include solid dose, semi-solid dose, orals, liquids and topicals with dedicated facilities for Hormone products, Steroidal products and also dedicated antibiotics (Cephalosporins)
Expertise in product dossier preparation from concept stage through to regulatory submission, inclusive of R&D batches, stability, process validation, and all analytical methodology requirements to facilitate the preparation and submission of CTD dossiers to suit any regulatory environment.
Product dossiers can be purchased, licensed and supported by product manufacturing at this facility and delivered FIS in either bulk or finished pack form. Single window clearance utilizing ultra modern seaport managed by Maersk Sealand.
| Tablets: | 870 million tabs | |
|
|
General | 300 million |
| Hormones | 270 million | |
| Antibiotics | 300 million | |
| Capsules: | 288 million caps | |
|
General |
144 million | |
| Antibiotic | 144 million | |
| Oral Liquids: | ||
| General | 12 million bottles | |
| Dry Syrup: | ||
| Antibiotic | 7.2 million bottles | |
| Semi-solids: | 15.6 million tubes | |
| General | 6.0 million | |
| Hormones | 3.6 million | |
| Steroids | 6.0 million | |
| Packaging: | 120 million blisters | |
|
PVC/ALU, ALU/ALU, ALU Strips |
||
- Large Production Capacities with flexibility in batch sizes
Oman Pharmaceutical Products Co. supply chain management utilizes Expertise sourced from the Indian subcontinent as well as providing low labor, energy and tax costs.